PLX News and Press, Protalix BioTherapeutics Inc. From 03/14/24

2024-03-14 06:51:52 ET More on Protalix BioTherapeutics Seeking Alpha’s Quant Rating on Protalix BioTherapeutics Historical earnings data for Protalix BioTherapeutics Financial information for Protalix BioTherapeutics Read the full article on Seeking...

2024-03-13 12:32:00 ET More on Protalix BioTherapeutics Seeking Alpha’s Quant Rating on Protalix BioTherapeutics Historical earnings data for Protalix BioTherapeutics Financial information for Protalix BioTherapeutics Read the full article on Seeking...

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 PR Newswire Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, I...

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference PR Newswire Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET ...

2024-01-26 08:32:05 ET Losers: Aclarion ( ACON ) 119% . Panbela Therapeutics ( PBLA ) 59% . Processa Pharmaceuticals ( PCSA ) 29% . Corbus Pharmaceuticals Holdings ( CRBP ) 23% . as targeting antibody drug conjugate demonstrates encouragin...

2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...

Protalix BioTherapeutics Issues 2024 Letter to Stockholders PR Newswire CARMIEL, Israel , Dec. 26, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization o...

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-cla...

2023-11-17 16:16:33 ET Summary Protalix shows mixed financials with declining revenue, yet improved operating loss, indicating increasing operational efficiency. PRX-115, in Phase I trials for refractory gout, is crucial in a competitive market with high efficacy and safety standa...

2023-11-06 11:57:05 ET Protalix Biotherapeutics, Inc. (PLX) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Dror Bashan - President and Chief Executive Officer Eyal Rubin - Sen...